The contribution of systems biology and reverse genetics to the understanding of Kaposi's sarcoma-associated herpesvirus pathogenesis in endothelial cells

Thrombosis and Haemostasis

Volumn 102, Issue 6, 2009, Pages 1117-1134

  Stürzl, Michael ^a   Konrad, Andreas ^a   Alkharsah, Khaled R ^b   Jochmann, Ramona ^a   Thurau, Mathias ^a   Marquardt, Gaby ^a   Schulz, Thomas F ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiogenesis; Apoptosis; Endothelial cells; Interferon; NF kappaB

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; FLICE INHIBITORY PROTEIN; INTERLEUKIN 6; LATENCY ASSOCIATED NUCLEAR ANTIGEN; TRANSCRIPTOME;

BINDING SITE; CELLULAR DISTRIBUTION; ENDOTHELIUM CELL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; K1 VIRUS GENE; K15 VIRUS GENE; K2 VIRUS GENE; K8 1 VIRUS GENE; NONHUMAN; ORF45 VIRUS GENE; ORF50 VIRUS GENE; ORF57 VIRUS GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, VIRAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, TRANSGENIC; PROTEOMICS; SARCOMA, KAPOSI; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; VIRAL PROTEINS;

EID: 72949100330     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-07-0472     Document Type: Review

References (207)

1. Chang Y, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
2. Buonaguro FM, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65: 25-28.
3. Carbone A, Gaidano G. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Br J Haematol 1997; 97: 515-522.
4. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332: 1181-1185.
5. Strauchen JA, et al. Body cavity-based malignant lymphoma containing Kaposi sarcoma-associated herpesvirus in an HIV-negative man with previous Kaposi sarcoma. Ann Intern Med 1996; 125: 822-825.
6. Stürzl M, et al. Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001; 81: 125-159.
7. Gill J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31: 384-390.
8. Dittmer DP, Krown SE. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007; 19: 452-457.
9. Trattner A, et al. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993; 72: 1779-1783.
10. Schena M, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-470.
11. Smith RD, et al. Rapid quantitative measurements of proteomes by Fourier transform ion cyclotron resonance mass spectrometry. Electrophoresis 2001; 22: 1652-1668.
12. Unlu M, et al. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-2077.
13. Gavin AC, et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002; 415: 141-147.
14. Luo Y, et al. Mammalian two-hybrid system: a complementary approach to the yeast two-hybrid system. Biotechniques 1997; 22: 350-352.
15. Rigaut G, et al. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 1999; 17: 1030-1032.
16. Uetz P, et al. A comprehensive analysis of proteinprotein interactions in Saccharomyces cerevisiae. Nature 2000; 403: 623-627.
17. Ziauddin J, Sabatini DM. Microarrays of cells expressing defined cDNAs. Nature 2001; 411: 107-110.
18. Renne R, et al. Lytic growth of Kaposi's sarcomaassociated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996; 2: 342-346.
19. Zhong W, et al. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci USA 1996; 93: 6641-6646.
20. Song MJ, et al. Transcription activation of polyadenylated nuclear rna by rta in human herpesvirus 8/Kaposi's sarcoma-associated herpesvirus. J Virol 2001; 75: 3129-3140.
21. Staskus KA, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997; 71: 715-719.
22. Stürzl M, et al. Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma. Int J Cancer 1997; 72: 68-71.
23. Sarid R, et al. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 1998; 72: 1005-1012.
24. Jenner RG, et al. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 2001; 75: 891-902.
25. Paulose-Murphy M, et al. Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol 2001; 75: 4843-4853.
26. Nakamura H, et al. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol 2003; 77: 4205-4220.
27. Krishnan HH, et al. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 2004; 78: 3601-3620.
28. Ishido S, et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 2000; 13: 365-374.
29. Stürzl M, et al. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 1999; 91: 1725-1733.
30. Poole LJ, et al. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002; 76: 3395-3420.
31. Moses AV, et al. Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol 1999; 73: 6892-6902.
32. Moses AV, et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002; 76: 8383-8399.
33. Raggo C, et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res 2005; 65: 5084-5095.
34. Akula SM, et al. Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 2002; 108: 407-419.
35. Naranatt PP, et al. Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity. J Virol 2003; 77: 1524-1539.
36. Naranatt PP, et al. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 2004; 64: 72-84.
37. Naschberger E, et al. Nuclear factor-kappaB motif and interferon-alpha-stimulated response element cooperate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells. Biochem J 2004; 379: 409-420.
38. Guenzi E, et al. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. Embo J 2003; 22: 3772-3782.
39. Guenzi E, et al. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. Embo J 2001; 20: 5568-5577.
40. Weinländer K, et al. Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha4 expression. FASEB J 2008; 22: 4168-4178.
41. Naschberger E, et al. Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 2008; 123: 2120-2129.
42. Cornali E, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996; 149: 1851-1869.
43. Thewes M, et al. The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study. Int J Dermatol 2000; 39: 188-191.
44. Babon JJ, et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol Cell 2006; 22: 205-216.
45. Croker BA, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003; 4: 540-545.
46. Croker BA, et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004; 20: 153-165.
47. Dupin N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999; 96: 4546-4551.
48. Stürzl M, et al. Kaposi's sarcoma: a review of gene expression and ultrastructure of KS spindle cells in vivo. AIDS Res Hum Retroviruses 1992; 8: 1753-1763.
49. Weninger W, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-251.
50. Wang HW, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36: 687-693.
51. Petrova TV, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002; 21: 4593-4599.
52. Hong YK, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36: 683-685.
53. Vart RJ, et al. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 2007; 67: 4042-4051.
54. Gale NW, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3: 411-423.
55. Fiedler U, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-239.
56. Makinen T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
57. Veikkola T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-1231.
58. Glaunsinger BA, Ganem DE. Messenger RNA turnover and its regulation in herpesviral infection. Adv Virus Res 2006; 66: 337-394.
59. Chandriani S, Ganem D. Host transcript accumulation during lytic KSHV infection reveals several classes of host responses. PLoS ONE 2007; 2: e811.
60. Polson AG, et al. Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2002; 62: 4525-4530.
61. Herndier BG, et al. Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. Aids 1994; 8: 575-581.
62. Glaunsinger B, Ganem D. Highly selective escape from KSHV-mediated host mRNA shutoff and its implications for viral pathogenesis. J Exp Med 2004; 200: 391-398.
63. Chaudhary PM, et al. Modulation of the NF-kappa B pathway by virally encoded death effector domainscontaining proteins. Oncogene 1999; 18: 5738-5746.
64. Djerbi M, et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999; 190: 1025-1032.
65. Efklidou S, et al. vFLIP from KSHV inhibits anoikis of primary endothelial cells. J Cell Sci 2008; 121: 450-457.
66. Konrad A, et al. A systems biology approach to identify the combination effects of human herpesvirus 8 genes on NF-kappaB activation. J Virol 2009; 83: 2563-2574.
67. Sun Q, et al. The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation. Blood 2003; 101: 1956-1961.
68. Mehrad B, et al. Chemokines as mediators of angiogenesis. Thromb Haemost 2007; 97: 755-762.
69. Sakakibara S, et al. Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells. J Virol 2009; 83: 2140-2153.
70. Thurau M, et al. Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death. J Virol 2009; 83: 598-611.
71. Cocchi F, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
72. Blasig C, et al. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol 1997; 71: 7963-7968.
73. Stürzl M, et al. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 1992; 89: 7046-7050.
74. Zhu FX, et al. Virion proteins of Kaposi's sarcomaassociated herpesvirus. J Virol 2005; 79: 800-811.
75. Nealon K, et al. Lytic replication of Kaposi's sarcoma-associated herpesvirus results in the formation of multiple capsid species: isolation and molecular characterization of A, B, and C capsids from a gammaherpesvirus. J Virol 2001; 75: 2866-2878.
76. Russo JJ, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996; 93: 14862-14867.
77. Rozen R, et al. Virion-wide protein interactions of Kaposi's sarcoma-associated herpesvirus. J Virol 2008; 82: 4742-4750.
78. Si H, et al. Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol 2006; 80: 9017-9030.
79. Ballestas ME, Kaye KM. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol 2001; 75: 3250-3258.
80. Si H, et al. Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol 2008; 82: 6734-6746.
81. Kaul R, et al. Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology 2007; 364: 317-329.
82. Ma L, et al. Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci 2006; 13: 205-213.
83. Uetz P, et al. Herpesviral protein networks and their interaction with the human proteome. Science 2006; 311: 239-242.
84. Chen J, et al. Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA. Virology 2009; 386: 290-302.
85. Ellison TJ, et al. A comprehensive analysis of recruitment and transactivation potential of K-Rta and K-bZIP during reactivation of Kaposi's sarcoma-associated herpesvirus. Virology 2009; 387: 76-88.
86. Sander G, et al. Intracellular Localization Map of HHV-8 Proteins. J Virol 2008; 82: 1908-1922.
87. Simpson JC, et al. Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing. EMBO Rep 2000; 1: 287-292.
88. Salsman J, et al. Genome-wide screen of three herpesviruses for protein subcellular localization and alteration of PML nuclear bodies. PLoS Pathog 2008; 4: e1000100.
89. Mathas S, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199: 1041-1052.
90. Niikura Y, et al. Monitoring of caspase-8/FLICE processing and activation upon Fas stimulation with novel antibodies directed against a cleavage site for caspase-8 and its substrate, FLICE-like inhibitory protein (FLIP). J Biochem (Tokyo) 2002; 132: 53-62.
91. Matta H, et al. A nuclear role for Kaposi's sarcomaassociated herpesvirus-encoded K13 protein in gene regulation. Oncogene 2008; 27: 5243-5253.
92. Katano H, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269: 335-344.
93. Wu FY, et al. Origin-independent assembly of Kaposi's sarcoma-associated herpesvirus DNA replication compartments in transient cotransfection assays and association with the ORF-K8 protein and cellular PML. J Virol 2001; 75: 1487-1506.
94. Keller SA, et al. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96: 2537-2542.
95. Sadagopan S, et al. Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J Virol 2007; 81: 3949-3968.
96. Brown HJ, et al. NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 2003; 77: 8532-8540.
97. Ye FC, et al. Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol 2008; 82: 4235-4249.
98. Keller SA, et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006; 107: 3295-3302.
99. Sgarbanti M, et al. A requirement for NF-kappaB induction in the production of replication-competent HHV-8 virions. Oncogene 2004; 23: 5770-5780.
100. Brinkmann MM, et al. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J Virol 2003; 77: 9346-9358.
101. Schwarz M, Murphy PM. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol 2001; 167: 505-513.
102. Seo T, et al. Inhibition of nuclear factor kappaB activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus. Oncogene 2004; 23: 6146-6155.
103. Lee BS, et al. Suppression of tetradecanoyl phorbol acetate-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus by K1 signal transduction. J Virol 2002; 76: 12185-12199.
104. Prakash O, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 2005; 105: 3987-3994.
105. Stürzl M, et al. High throughput screening of gene functions in Mammalian cells using reversely transfected cell arrays: review and protocol. Comb Chem High Throughput Screen 2008; 11: 159-172.
106. Renne R, et al. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/ HHV-8) to SIV-positive and SIV-negative rhesus macaques. J Med Primatol 2004; 33: 1-9.
107. Parsons CH, et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest 2006; 116: 1963-1973.
108. Dittmer D, et al. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/ HHV-8) to SCID-hu Thy/Liv mice. J Exp Med 1999; 190: 1857-1868.
109. Foreman KE, et al. Injection of human herpesvirus-8 in human skin engrafted on SCID mice induces Kaposi's sarcoma-like lesions. J Dermatol Sci 2001; 26: 182-193.
110. Mutlu AD, et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007; 11: 245-258.
111. Schultz ER, et al. Characterization of two divergent lineages of macaque rhadinoviruses related to Kaposi's sarcoma-associated herpesvirus. J Virol 2000; 74: 4919-4928.
112. Greensill J, Schulz TF. Rhadinoviruses (gamma2-herpesviruses) of Old World primates: models for KSHV/HHV8-associated disease? AIDS 2000; 14 (Suppl 3): S11-19.
113. Desrosiers RC, et al. A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol 1997; 71: 9764-9769.
114. Rose TM, et al. Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J Virol 1997; 71: 4138-4144.
115. Greensill J, et al. A chimpanzee rhadinovirus sequence related to Kaposi's sarcoma-associated herpesvirus/ human herpesvirus 8: increased detection after HIV-1 infection in the absence of disease. Aids 2000; 14: F129-135.
116. Greensill J, et al. Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates? J Virol 2000; 74: 1572-1577.
117. Lacoste V, et al. KSHV-like herpesviruses in chimps and gorillas. Nature 2000; 407: 151-152.
118. Lacoste V, et al. Simian homologues of human gamma-2 and betaherpesviruses in mandrill and drill monkeys. J Virol 2000; 74: 11993-11999.
119. Alexander L, et al. The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. J Virol 2000; 74: 3388-3398.
120. Searles RP, et al. Sequence and genomic analysis of a Rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. J Virol 1999; 73: 3040-3053.
121. Mansfield KG, et al. Experimental infection of rhesus and pig-tailed macaques with macaque rhadinoviruses. J Virol 1999; 73: 10320-10328.
122. Wong SW, et al. Induction of B cell hyperplasia in
123. simian immunodeficiency virus- infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus [In Process Citation]. J Exp Med 1999; 190: 827-840.
124. An FQ, et al. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 2006; 80: 4833-4846.
125. Boshoff C, et al. Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 1998; 91: 1671-1679.
126. Staudt MR, et al. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004; 64: 4790-4799.
127. Wu W, et al. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res 2005; 29: 545-555.
128. Jeong JH, et al. Tissue specificity of the Kaposi's sarcoma-associated Herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virology 2002; 76: 11024-11032.
129. Fakhari FD, et al. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest 2006; 116: 735-742.
130. Verschuren EW, et al. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res 2004; 64: 581-589.
131. Verschuren EW, et al. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2002; 2: 229-241.
132. Chugh P, et al. Constitutive NF-{kappa}B activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc Natl Acad Sci USA 2005; 102: 12885-12890.
133. Grisotto MG, et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest 2006; 116: 1264-1273.
134. Guo HG, et al. Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 2003; 77: 2631-2639.
135. Jensen KK, et al. The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J Immunol 2005; 174: 3686-3694.
136. Montaner S, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23-36.
137. Yang TY, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000; 191: 445-454.
138. Prakash O, et al. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J Natl Cancer Inst 2002; 94: 926-935.
139. Zhou FC, et al. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 2002; 76: 6185-6196.
140. Lee H, et al. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol 1998; 18: 5219-5228.
141. Lee H, et al. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998; 4: 435-440.
142. Wang L, et al. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcomaassociated herpesvirus. Cancer Res 2006; 66: 3658-3666.
143. Lee BS, et al. Structural analysis of the Kaposi's sarcoma-associated herpesvirus K1 protein. J Virol 2003; 77: 8072-8086.
144. Lagunoff M, et al. Immunoreceptor tyrosinebased activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication. J Virol 2001; 75: 5891-5898.
145. Lagunoff M, et al. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1999; 96: 5704-5709.
146. Tomlinson CC, Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol 2004; 78: 1918-1927.
147. Wang L, et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 2004; 64: 2774-2781.
148. Moore PS, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274: 1739-1744.
149. Parravicini C, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirusinfected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156: 743-749.
150. Burger R, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998; 91: 1858-1863.
151. Hoischen SH, et al. Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem 2000; 267: 3604-3612.
152. Jones KD, et al. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999; 94: 2871-2879.
153. Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 1999; 94: 4247-4254.
154. Kovaleva M, et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol 2006; 80: 8510-8520.
155. Chen L, Lagunoff M. The KSHV viral interleukin-6 is not essential for latency or lytic replication in BJAB cells. Virology 2007; 359: 425-435.
156. Sathish N, et al. Kaposi's sarcoma-associated herpesvirus ORF45 interacts with kinesin-2 transporting viral capsid-tegument complexes along microtubules. PLoS Pathog 2009; 5: e1000332.
157. Zhu FX, et al. Functional characterization of Kaposi's sarcoma-associated herpesvirus ORF45 by bacterial artificial chromosome-based mutagenesis. J Virol 2006; 80: 12187-12196.
158. Abada R, et al. SIAH-1 interacts with the Kaposi's sarcoma-associated herpesvirus-encoded ORF45 protein and promotes its ubiquitylation and proteasomal degradation. J Virol 2008; 82: 2230-2240.
159. Zhu FX, King SM, Smith EJ, et al. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci USA 2002; 99: 5573-5578.
160. Sun R, et al. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1998; 95: 10866-10871.
161. Viejo-Borbolla A, Schulz TF. Kaposi's sarcomaassociated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev 2003; 5: 222-229.
162. Chang PJ, et al. Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol 2002; 76: 3168-3178.
163. Gwack Y, et al. Kaposi's Sarcoma-associated herpesvirus open reading frame 50 stimulates the transcriptional activity of STAT3. J Biol Chem 2002; 277: 6438-6442.
164. Liang Y, et al. The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev 2002; 16: 1977-1989.
165. Wang SE, et al. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol 2003; 77: 9590-9612.
166. Deng H, et al. Auto-activation of the rta gene of human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus. J Gen Virol 2000; 81: 3043-3048.
167. Xu Y, et al. A Kaposi's sarcoma-associated herpesvirus/ human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J Virol 2005; 79: 3479-3487.
168. Gruffat H, et al. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) encodes a homologue of the Epstein-Barr virus bZip protein EB1. J Gen Virol 1999; 80: 557-561.
169. Izumiya Y, et al. Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression. J Virol 2003; 77: 1441-1451.
170. Wang SE, et al. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lyticcycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP. J Virol 2003; 77: 600-623.
171. Park J, et al. The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. J Virol 2000; 74: 11977-11982.
172. Wu FY, et al. Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha. Proc Natl Acad Sci USA 2002; 99: 10683-10688.
173. Kato-Noah T, et al. Overexpression of the kaposi's sarcoma-associated herpesvirus transactivator K-Rta can complement a K-bZIP deletion BACmid and yields an enhanced growth phenotype. J Virol 2007; 81: 13519-13532.
174. Boyne JR, Colgan KJ, Whitehouse A. Recruitment of the complete hTREX complex is required for Kaposi's sarcoma-associated herpesvirus intronless mRNA nuclear export and virus replication. PLoS Pathog 2008; 4: e1000194.
175. Malik P, et al. The evolutionarily conserved Kaposi's sarcoma-associated herpesvirus ORF57 protein interacts with REF protein and acts as an RNA export factor. J Biol Chem 2004; 279: 33001-33011.
176. Majerciak V, et al. Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus. J Virol 2007; 81: 1062-1071.
177. Birkmann A, et al. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J Virol 2001; 75: 11583-11593.
178. Wang FZ, et al. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. J Virol 2001; 75: 7517-7527.
179. Luna RE, et al. Kaposi's sarcoma-associated herpesvirus glycoprotein K8.1 is dispensable for virus entry. J Virol 2004; 78: 6389-6398.
180. Xu Y, et al. Evaluation of the lytic origins of replication of Kaposi's sarcoma-associated virus/human herpesvirus 8 in the context of the viral genome. J Virol 2006; 80: 9905-9909.
181. Davis MA, et al. Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 1997; 89: 1868-1874.
182. Rainbow L, et al. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 1997; 71: 5915-5921.
183. Thome M, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-521.
184. Liu L, et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002; 277: 13745-13751.
185. Guasparri I, et al. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004; 199: 993-1003.
186. Grossmann C, et al. Activation of NF-kappaB by the latent vFLIP gene of
187. Ballestas ME, et al. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999; 284: 641-644.
188. Hu J, et al. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol 2002; 76: 11677-11687.
189. Barbera AJ, et al. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 2006; 311: 856-861.
190. Garber AC, et al. DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 2001; 75: 7882-7892.
191. Piolot T, et al. Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol 2001; 75: 3948-3959.
192. Viejo-Borbolla A, et al. A Domain in the C-terminal region of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated Herpesvirus affects transcriptional activation and binding to nuclear heterochromatin. J Virol 2003; 77: 7093-7100.
193. Friborg J, Jr., et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894.
194. Radkov SA, et al. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6: 1121-1127.
195. Krithivas A, et al. Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol 2002; 76: 11596-11604.
196. Krithivas A, Young DB, Liao G, et al. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol 2000; 74: 9637-9645.
197. Shamay M, et al. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci USA 2006; 103: 14554-14559.
198. Ottinger M, et al. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol 2006; 80: 10772-10786.
199. Platt GM, et al. Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol 1999; 73: 9789-9795.
200. Ye FC, et al. Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol 2004; 78: 11121-11129.
201. Li Q, et al. Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology 2008; 379: 234-244.
202. Staudt MR, Dittmer DP. Promoter switching allows simultaneous transcription of LANA and K14/vGPCR of Kaposi's sarcoma-associated herpesvirus. Virology 2006; 350: 192-205.
203. Stedman W, et al. Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. Embo J 2008; 27: 654-666.
204. Kang H, Lieberman PM. Cell cycle control of Kaposi's sarcoma-associated herpesvirus latency transcription by CTCF-cohesin interactions. J Virol 2009; 83: 6199-6210.
205. Choi JK, et al. Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. J Virol 2000; 74: 436-446.
206. Glenn M, et al. Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J Virol 1999; 73: 6953-6963.
207. Brinkmann MM, et al. Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 2007; 81: 42-58.